Rationale. The gene therapy program is highly dependent upon the generation and maintenance of transgenic and hybrid transgenic mice for the study of cystic fibrosis and other diseases. This core is designed to take advantage of established expertise in the generation of the transgenic mice for the study of lung disease and in gene ablation studies that will be required for the present program projects. Likewise, maintenance of germ-free transgenic lines will be critical in supplying genotyped mice for the various projects. This core will both generate the new transgenic lines and gene targeted mice, as well as maintain breeding and genotype analysis for the transgenic mice already generated, as required for the individual projects and investigators. This Core will: 1) provide animal husbandry, breeding, tail clip, Southern blot, PCR analysis for the established lines necessary for the present application; 2) generate all new transgenic lines described in the protocols by pronuclear injection and gene targeting; 3) facilitate long term maintenance and surveillance of viral exposed animals required for the various projects. The animals will be maintained in sterile- barrier caging in a separate, germ-free facility at the Children's Hospital Research Foundation under the direction of Gary Keller, D.V.M. This program includes sentinel mice and careful ongoing surveillance and screening for other pathogens. This aspect of Core will interact closely with the Clinical Viral Core for vector safety issues. Such surveillance will be critical in the evaluation of lung disease in our various transgenic models and be necessary for the interpretation of genetic vs. environmental effects on lung injury or development.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051832-05
Application #
6110318
Study Section
Project Start
1997-09-01
Project End
1998-08-31
Budget Start
Budget End
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Wert, Susan E; Whitsett, Jeffrey A; Nogee, Lawrence M (2009) Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol 12:253-74
Zsengeller, Z K; Ross, G F; Trapnell, B C et al. (2001) Adenovirus infection increases iNOS and peroxynitrite production in the lung. Am J Physiol Lung Cell Mol Physiol 280:L503-11
Zeng, X; Gray, M; Stahlman, M T et al. (2001) TGF-beta1 perturbs vascular development and inhibits epithelial differentiation in fetal lung in vivo. Dev Dyn 221:289-301
Iwamoto, H S; Trapnell, B C; McConnell, C J et al. (1999) Pulmonary inflammation associated with repeated, prenatal exposure to an E1, E3-deleted adenoviral vector in sheep. Gene Ther 6:98-106
Zsengeller, Z K; Halbert, C; Miller, A D et al. (1999) Keratinocyte growth factor stimulates transduction of the respiratory epithelium by retroviral vectors. Hum Gene Ther 10:341-53
Schwarz, Y A; Amin, R S; Stark, J M et al. (1999) Interleukin-1 receptor antagonist inhibits interleukin-8 expression in A549 respiratory epithelial cells infected in vitro with a replication-deficient recombinant adenovirus vector. Am J Respir Cell Mol Biol 21:388-94
Otake, K; Ennist, D L; Harrod, K et al. (1998) Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 9:2207-22
Jain-Vora, S; LeVine, A M; Chroneos, Z et al. (1998) Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa. Infect Immun 66:4229-36
Zeng, X; Wert, S E; Federici, R et al. (1998) VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo. Dev Dyn 211:215-27
Weaver, T E (1998) Synthesis, processing and secretion of surfactant proteins B and C. Biochim Biophys Acta 1408:173-9

Showing the most recent 10 out of 44 publications